© Matteo Bonazzi, Edith Gouin
Observation en immunofluorescence d'une cellule infectée par Listeria monocytogenes. En bleu: marquage des protéines de surface de Listeria qui permet de visualiser les bactéries. En rouge et vert: marquage de l'actine, une protéine qui forme le cytosquelette des cellules. Les Listeria utilisent l'actine cellulaire pour former des "comêtes" et se déplacer à l'intérieur des cellules qu'elles infectent.Cell infected by Listeria monocytogenes. The surface proteins (in blue) of Listeria enable us to view the bacteria. Actin, a constituent protein of cells, is shown in red and green.

Antibodies in Therapy and Pathology


Antibodies in Therapy & Pathology (INSERM U.760): from Allergy & Autoimmunity to Cancer Immunotherapy

                Antibodies are key effectors of the immune system. They are responsible for disease induction (autoimmunity, allergy) and can be protecting from or facilitating infections and tumors. Antibodies do not exert by themselves, however, biological functions: these are mainly mediated by antibody receptors (FcRs).


 – Decipher the role of human antibodies, human antibody receptors (FcRs) and the cells expressing them during therapy and in the induction of pathologies.

Establish high-throughput plasma cell selection using droplet microfluidics to generate the “anatomical map” of antigen-specific plasma cells, and demonstrate the pathogenic nature of antibodies in specific diseases.

     How antibodies and their receptors induce/regulate autoimmune and allergic diseases is addressed using on one hand models of rheumatoid arthritis and anaphylaxis (allergic shock) in humanized mice and, on the other hand through a clinical study (NASA).

     How antibodies and their receptors participate in passive antibody therapy is addressed using human tumor xenografts in the mouse.

     How antigen-specific plasma cells disseminate in vivo and to identify antibodies at high-throughput is addressed using droplet-based microfluidic technologies developed at ESPCI-ParisTech

In most projects, we aim at identifying the cell population(s) responsible for antibody-mediated effects, and decipher the mechanism behind their contribution to therapy or pathology. To enhance the clinical relevance of our studies in mice, we have generated “humanized” mouse models expressing human FcRs in the presence of human antibodies. Our recent focus has been on FcR-expressing myeloid cells, in particular neutrophils and monocytes/macrophages, that we extend now to platelets and their interaction with neutrophils.

 Altogether, our research, integrating fundamental, clinical and industry-driven approaches, aims at elucidating the role of antibodies, their receptors and the cells expressing them in major disease and therapy models and, hopefully, propose novel therapeutic solutions in antibody-based therapies.


– Identification of neutrophils as the cell population responsible for anti-tumor immunotherapy of solid tumors (Albanesi et al, Blood 2013).

– Demonstration that human IgG receptor (FcγRI,CD64) can trigger autoimmune and allergic diseases, and that it can mediate anti-tumor antibody therapy (Mancardi et al, Blood 2013).

– Demonstration that mouse FcγRIII (CD16) and mouse FcγRI (CD64) are responsible for anti-melanoma antibody therapy in a syngeneic mouse metastatic melanoma model (Albanesi et al., J Immunol Cutting Edge 2012)

– Demonstration that human IgG receptor (FcγRIIA,CD32A) can trigger anaphylaxis and airway inflammation (Jönsson et al, Blood 2012).

– Demonstration that neutrophils are the main inducers of active anaphylaxis in the mouse and that human neutrophils can induce anaphylaxis (Jönsson & Mancardi et al, J Clin Invest 2011).



  • Agence_Nationale_de_la_Recherche
  • logo_erc copie
  • ARC
  • logo-ligue-contre-le-cancer_01
  • inserm_1
  • institut-pasteur-c
  • logo balsan


  • milieu_interieur



Antibodies & Complement: Effector Functions, Therapies & Technologies 2017

20th – 23rd June 2017

By NIAID (B12 antibody) [CC BY 2.0 (http://creativecommons.org/licenses/by/2.0)], via Wikimedia CommonsWe are proud to announce the 1st Zing Antibodies & Complement: Effector Functions, Therapies & Technologies Conference will take place in June 2017 in Portugal.

The antibody response and the complement system are major effector arms of the immune system. Both have been involved in a plethora of pathological conditions – including autoimmunity, allergy, infections and cancer- and regulate, mainly through their receptors (FcR and CR respectively) cell activation, migration, survival but also metabolism. As the portfolio of antibody- and complement-effector function grow, high-end technological solutions are developed and novel therapeutic applications are proposed.


This Zing conference will focus attention on key advances in both fields with the aim at fostering discussions between antibody experts and complement experts. Some of the critical topics to be covered include

  • Antibody & complement functions
  • FcR and CR
  • Ab glycosylation and anti-inflammatory activity
  • Structure – function linkage
  • Novel technologies
  • Complement and antibody therapies

This Antibody & Complement meeting will be a forum for leaders in the field and new investigators coming from academia, industry and research institutes to discuss where the field is going and what challenges lie ahead.


Email: pierre.bruhns@pasteur.fr

Antibodies in Therapy and Pathology
25 Rue du Docteur Roux
75015, Paris